Humalog Mix50 Kwikpen (Insulin Lispro)

Humalog Mix50 Kwikpen is indicated for the treatment of diabetes mellitus where rapid glucose control is required.

• Management of Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen.
• Management of Type 2 diabetes mellitus when additional prandial insulin is needed.
• Mealtime (prandial) insulin coverage to control post‑meal glucose spikes.
• Use in combination with oral antidiabetic agents for comprehensive glycemic control.
• Flexible dosing for patients who require variable insulin amounts throughout the day.
• Suitable for patients transitioning from multiple daily injections to a pen‑based system.

• Insulin lispro binds to insulin receptors on muscle, adipose, and hepatic cells, activating the receptor's intrinsic tyrosine kinase activity. This triggers intracellular signaling cascades that promote translocation of glucose transporter type 4 (GLUT4) to the cell membrane, enhancing glucose uptake from the bloodstream. The rapid‑acting analog also suppresses hepatic glucose production, leading to a swift reduction in blood glucose levels after subcutaneous administration.

Adverse reactions to Humalog Mix50 Kwikpen may vary in frequency and severity.

Common

• Mild hypoglycemia, characterized by shakiness, sweating, or dizziness.
• Localized injection‑site redness, swelling, or itching.
• Development of lipohypertrophy or lipoatrophy at repeated injection sites.

Serious

• Severe hypoglycemia with loss of consciousness or seizures.
• Allergic reactions ranging from urticaria to anaphylaxis.
• Significant edema or fluid retention, especially in the lower extremities.

Before using Humalog Mix50 Kwikpen, consider the following safety points.

• Verify blood glucose levels regularly to avoid hypoglycemia.
• Adjust insulin dose during illness, pregnancy, or changes in physical activity.
• Monitor for signs of allergic reactions, especially after the first few doses.
• Use a new injection site each time to reduce the risk of lipodystrophy.
• Store the pen according to manufacturer instructions; do not use if the solution is discolored.
• Inform healthcare providers of any history of cardiovascular disease or renal impairment.

Certain medications and substances can affect the action of Humalog Mix50 Kwikpen.

Avoid

• Concurrent use of other rapid‑acting insulins or high‑dose insulin analogs without medical supervision.
• Beta‑blockers that may mask hypoglycemia symptoms.
• Alcohol excess, which can potentiate insulin‑induced hypoglycemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require dose adjustments.
• Thyroid hormones or thyroid replacement therapy, which can alter insulin requirements.